KEYNOTE-991
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
- NCT04191096 ↗
- Terminated
- Merck Sharp & Dohme LLC
- Standard
We haven't built an HCP commentary report on KEYNOTE-991 (pembrolizumab plus enzalutamide in metastatic hormone-sensitive prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KEYNOTE-991 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 11 | |
| Podcasts | 4 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Metastatic Hormone-Sensitive Prostate Cancer
- Interventions
- Pembrolizumab; Enzalutamide; Androgen Deprivation Therapy (ADT); Placebo
- Arms
- Pembrolizumab + Enzalutamide + ADT · Experimental
- Placebo + Enzalutamide + ADT · Placebo comparator
- Enrollment
- 1,251
- Primary outcomes
- Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Feb 12, 2020
- Primary completion
- Oct 31, 2022
- Results posted
- Yes
- Registry record
- NCT04191096 · updated Sep 28, 2026
Publications
linked from the registry- Gratzke C, Kwiatkowski M, De Giorgi U, Martins da Trindade K, De Santis M, Armstrong AJ, Niu C, Liu Y, Poehlein CH. KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer. Future Oncol. 2023 Jan 27. doi: 10.2217/fon-2022-0776. Online ahead of print. PubMed 36705526